Asset Details
Do you wish to reserve the book?
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
Do you wish to request the book?
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk
2022
Overview
In two articles in this issue of the
Journal
, the members of the GRADE Study Research Group
1,2
report the findings of the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study, which involved participants who had type 2 diabetes without established cardiovascular complications. These articles have been awaited with great anticipation. Most advances related to cardiovascular benefit in the treatment of type 2 diabetes have been derived from cardiovascular outcome trials involving participants with previous cardiovascular disease, and these advances have been related to secondary prevention. On the basis of those trials, the availability of two new . . .
